Cancer cells grown in our 3D models secrete exosomes enriched with tumor-specific cargo. We use an Omics screening approach to identify novel biomarkers in these exosomes. Our first proprietary biomarker for prostate cancer outperformed PSA, the current clinical standard, in a retrospective clinical analysis. Now we are developing a reagent kit for the prostate cancer test to be administered at point-of-care, and expanding discovery efforts to pancreatic and ovarian cancer as new indications.
